Acumen Pharmaceuticals (ABOS)

• Market cap: $83.6M
• 1 day: -5.48%
• 5 days: -18.82%
• 1 month: 18.97%
• 3 months: 31.43%
• 6 months: -12.10%
• Year to date: -25.41%
• 1 year: -58.05%
• 5 years: -93.13%
• 10 years: -93.13%
• Sector: Healthcare
• Industry: Biotechnology

About: Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Employees: 52

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

22% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 9

1% more funds holding

Funds holding: 79 [Q4 2024] → 80 (+1) [Q1 2025]

3.77% less ownership

Funds ownership: 70.74% [Q4 2024] → 66.97% (-3.77%) [Q1 2025]

33% less call options, than puts

Call options by funds: $45K | Put options by funds: $67K

39% less capital invested

Capital invested by funds: $73.1M [Q4 2024] → $44.8M (-$28.3M) [Q1 2025]

55% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 33

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4 190% upside
• Avg. target: $4 190% upside
• High target: $4 190% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Citigroup Geoff Meacham

190% upside $4

Buy Initiated

17 Jun 2025